Ultragenyx Faces Legal Action Over Allegations of Misleading Setrusumab Effectiveness Claims

Ultragenyx Faces Legal Scrutiny Over Misleading Statements Regarding Setrusumab Effectiveness

Ultragenyx Pharmaceutical Inc. is currently embroiled in allegations of securities fraud connected to its experimental drug, setrusumab, designed for treating Osteogenesis Imperfecta (OI). A series of class action lawsuits have emerged, asserting that the company misrepresented the drug's efficacy during pivotal clinical trials, particularly the Phase III Orbit and Cosmic studies. Shareholders are urged to take action as the legal timelines for participation in the lawsuits are fast approaching. The claims center on Ultragenyx's alleged failure to adequately disclose critical information about the drug’s clinical performance, which has reportedly created undue investor optimism.

The lawsuits state that Ultragenyx made misleading claims about setrusumab's potential to significantly increase bone density and reduce fracture rates, reflecting an overly optimistic viewpoint based on flawed data. During the class period of August 3, 2023, to December 26, 2025, company representatives purportedly assured shareholders about the drug's effectiveness, despite indications that the clinical trials did not achieve their primary endpoints. Specifically, the Phase III studies reportedly failed to demonstrate statistically significant improvements regarding annualized fracture rates, which investor presentations had heavily emphasized. The disclosure of these results led to considerable portfolio losses, including a dramatic drop in share price from $34.19 to $19.72 in a single day.

As shareholders face uncertainty, law firms like The Gross Law Firm and Kroger, Topaz, Meltzer & Check, LLP are mobilizing efforts to represent the affected investors. Potential participants in the lawsuits are being urged to act before the April 6, 2026 deadline for registering as lead plaintiffs. The firms emphasize that joining the class action imposes no financial burden on participants, enabling investors who believe they have suffered losses due to the alleged misrepresentation to seek recovery without upfront costs.

In a broader industry context, the situation underscores the critical importance of transparency in clinical trial results for biopharmaceutical companies. Investors increasingly rely on company communications regarding drug efficacy, and misleading claims can result in significant financial implications. As Ultragenyx navigates this legal challenge, the outcomes could have lasting effects on how biopharmaceutical firms engage and report on drug trials, emphasizing a need for accountability in the rare disease therapeutic landscape.